News

Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection

Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection

WFMZ | Study is expected to provide insights into mechanisms of protection against staph infection. IBT and its subsidiary Integrated BioTherapeutic Vaccines (IBV) are developing IBT-V02, a novel vaccine for S. aureus infections with support from CARB-X and Novo Holdings. IBT-V02 will enter Phase 1 clinical trial this year.

Full Story